These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 26657792)
1. Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate. Zhang W; Zang N; Jiang Y; Chen P; Wang X; Zhang X Sci Rep; 2015 Dec; 5():17888. PubMed ID: 26657792 [TBL] [Abstract][Full Text] [Related]
2. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053 [TBL] [Abstract][Full Text] [Related]
3. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Zhang X; Zang N; Wei Y; Yin J; Teng R; Seftel A; Disanto ME Am J Physiol Endocrinol Metab; 2012 Jan; 302(2):E243-53. PubMed ID: 22028410 [TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Wang C Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of Oxytocin Receptor in the Hyperplastic Prostate. Li Z; Xiao H; Wang K; Zheng Y; Chen P; Wang X; DiSanto ME; Zhang X Front Endocrinol (Lausanne); 2018; 9():403. PubMed ID: 30123183 [No Abstract] [Full Text] [Related]
7. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. Ückert S; Waldkirch ES; Merseburger AS; Kuczyk MA; Oelke M; Hedlund P World J Urol; 2013 Jun; 31(3):609-14. PubMed ID: 23475211 [TBL] [Abstract][Full Text] [Related]
9. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934 [TBL] [Abstract][Full Text] [Related]
10. Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 Jin S; Xiang P; Liu J; Yang Y; Hu S; Sheng J; He Q; Yu W; Han W; Jin J; Peng J Prostate; 2019 Jun; 79(8):909-919. PubMed ID: 30958912 [TBL] [Abstract][Full Text] [Related]
11. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639 [TBL] [Abstract][Full Text] [Related]
13. Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. He W; Xiang H; Liu D; Liu J; Li M; Wang Q; Qian Q; Li Y; Fu X; Chen P; Guo Y; Zeng G; Wu Z; Zhan D; Wang X; DiSanto ME; Zhang X J Cell Mol Med; 2020 Nov; 24(22):13181-13195. PubMed ID: 33009887 [TBL] [Abstract][Full Text] [Related]
14. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. Bisegna C; Gravina GL; Pierconti F; Martini M; Larocca L; Rossi P; Grimaldi P; Dolci S; Di Stasi S; Jannini EA Andrology; 2020 Mar; 8(2):427-433. PubMed ID: 31433119 [TBL] [Abstract][Full Text] [Related]
15. The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. Lee YC; Wu WJ; Liu CC; Wang CJ; Li WM; Huang CH; Yeh HC; Ke HL; Huang SP J Sex Med; 2009 Nov; 6(11):3158-65. PubMed ID: 19515207 [TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. Morelli A; Sarchielli E; Comeglio P; Filippi S; Mancina R; Gacci M; Vignozzi L; Carini M; Vannelli GB; Maggi M J Sex Med; 2011 Oct; 8(10):2746-60. PubMed ID: 21812935 [TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. Zhao C; Kwan Park J Low Urin Tract Symptoms; 2012 Mar; 4 Suppl 1():75-80. PubMed ID: 26676704 [TBL] [Abstract][Full Text] [Related]
18. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163 [TBL] [Abstract][Full Text] [Related]
19. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452 [TBL] [Abstract][Full Text] [Related]
20. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. Kedia GT; Uckert S; Jonas U; Kuczyk MA; Burchardt M World J Urol; 2008 Dec; 26(6):603-9. PubMed ID: 18607596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]